Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS

(ALXN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2019 4 766 M
EBIT 2019 2 623 M
Net income 2019 1 760 M
Finance 2019 1 191 M
Yield 2019 -
Sales 2020 5 445 M
EBIT 2020 2 931 M
Net income 2020 1 993 M
Finance 2020 2 751 M
Yield 2020 -
P/E ratio 2019 16,12
P/E ratio 2020 14,27
EV / Sales2019 5,65x
EV / Sales2020 4,66x
Capitalization 28 104 M
More Financials
Company
Alexion Pharmaceuticals specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers. At the end of 2017, the group had a portfolio of 5 products in clinical development. Net sales are distributed... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
05/17ALEXION PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Hold..
AQ
05/13ALEXION PHARMACEUTICALS : to Present at the RBC Capital Markets Annual Healthcar..
BU
05/13ALEXION PHARMACEUTICALS : to Present at the UBS Global Healthcare Conference
BU
05/06ALEXION PHARMACEUTICALS : New England Journal of Medicine Publishes Positive Pha..
AQ
05/03ALEXION PHARMACEUTICALS : New England Journal of Medicine Publishes Positive Pha..
BU
04/29ALEXION PHARMACEUTICALS : Receives Positive CHMP Opinion for ULTOMIRIS in Adults..
AQ
04/26ALEXION PHARMACEUTICALS : Receives Positive CHMP Opinion for ULTOMIRIS® (ravuliz..
BU
04/25ALEXION PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
04/25ALEXION PHARMACEUTICALS : Raises Outlook After Strong First Quarter
DJ
04/25ALEXION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
AQ
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS
More recommendations
Sector news : Biopharmaceuticals
05:14pNOVARTIS : At $2 Million, New Novartis Drug Is Priciest Ever
DJ
04:36pNOVARTIS : Correction to Novartis Article
DJ
03:33pNOVARTIS : FDA Approves Novartis' Piqray for Breast Cancer
DJ
02:26pNOVARTIS' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $2.12..
DJ
02:07pSAMSUNG ELECTRONICS : South Korea orders further arrests at Samsung Electronics ..
RE
More sector news : Biopharmaceuticals
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 162 $
Spread / Average Target 29%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP, Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS31.01%28 104
CSL LIMITED11.36%64 281
BIOGEN-23.86%44 423
SAMSUNG BIOLOGICS CO LTD--.--%16 916
GRIFOLS1.88%15 837
BIOMARIN PHARMACEUTICAL INC.2.14%15 574